Article Retrospective analysis of 1217 IVF cycles in women aged 40 years and older

Size: px
Start display at page:

Download "Article Retrospective analysis of 1217 IVF cycles in women aged 40 years and older"

Transcription

1 RBMOnline - Vol 14. No Reproductive BioMedicine Online; on web 5 February 2007 Article Retrospective analysis of 1217 IVF cycles in women aged 40 years and older Avi Tsafrir received his MD in 1998 from the Hebrew University in Jerusalem. He completed his residency in Obstetrics and Gynaecology at Hadassah Medical Center, Israel, in He is currently a specialist registrar in the IVF unit of Shaare-Zedek Medical Center, Jerusalem. His research is in the field of infertility with emphasis on treatments for advanced maternal age women and health surveillance of children conceived through assisted reproduction treatment. In collaboration with a team from the Hebrew University in Jerusalem, he studies endometrial gene expression of patients with repeated IVF failure. Dr Avi Tsafrir A Tsafrir 1, A Simon, A Revel, B Reubinoff, A Lewin, N Laufer IVF Unit, Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Centres Ein-Kerem, PO Box 12000, Jerusalem 91120, Israel 1 Correspondence: Fax ; avits@netvision.net.il Abstract Older women comprise an increasing portion of patients entering assisted reproduction programmes. This study is a retrospective summary of the files of all patients aged 40 years and older at advent of IVF, between 1995 and 2004, in the authors centre. In all, 381 women underwent 1217 initiated treatment cycles. Embryo transfer was performed in 62.6% of initiated cycles. Success rates declined with each year after age 40; pregnancy and delivery rates were 13.9 and 9.1% at age 40 and 2.8 and 0.7% at age 45. There were no deliveries at an older age. Logistic regression analysis showed the following factors were independently and significantly related to higher pregnancy rates: younger age, lower dose of gonadotrophins, greater number of mature follicles, endometrial thickness, and number of embryos transferred; prior pregnancy did not influence success. Retrieving more than four oocytes increased pregnancy rates in all women over 40. Transferring 3 embryos or more increased pregnancy rates in all ages, but reached statistical significance only in women aged (P < 0.000). It is concluded that in women between 40 and 41 years of age, ovarian response is a major determinant of success, but not in women older than that. Unrealistic expectations may be avoided if accurate data are provided regarding delivery rates per year after age 40. Keywords: advanced maternal age, delivery rate, IVF, pregnancy rate Introduction 348 Women in their late 30s are considered to be of advanced age when attempting to conceive. Both fecundity for spontaneous conceptions and the success rate of assisted conception are markedly reduced (te Velde and Pearson, 2002; Baird et al., 2005). Ovarian and oocyte senescence that may begin as early as the 3rd decade of a woman s life are the predominant causes of embryo and pregnancy loss in older women (Armstrong, 2001). Maternal age has impacts on pregnancy and delivery rates even after multiple IVF cycles (Check et al., 1994). In a large retrospective study of consecutive single, double and triple transfers, where all embryos were of identical quality score and identical cleavage stage, a highly significant decrease in oocyte recovery and in implantation rate with increasing age was found to be almost linear, decreasing by approximately 1.5% per year (Ziebe et al., 2001). Moreover, the statistics of the outcome measure, a live healthy baby at term, are poorer than those of younger women using assisted technologies. In a very large series of women older than 40 years with low basal FSH at initiation of IVF, the cumulative live birth rate at age 40 years was 28%, but 0% at age 46 years (Klipstein et al., 2005). Thus outcomes of pregnancies for older women, a growing number with each decade as lifestyle decisions are increasingly divergent from those of previous decades, need to be more fully documented in order to obtain the best possible clinical perspective on an often long and costly endeavour (Legro et al., 1997; Chambers et al., 2006). When pregnant, however, the perinatal outcome of older and even post-menopausal women is generally reassuring (Antinori et al., 2003) Published by Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB3 8DB, UK

2 In Israel, the national health insurance covers most infertility treatments, including IVF, for the first two children. The age limit for performing IVF with the woman s own oocytes is 45 years, but there is no limit to the number of treatment cycles. On the other hand, the number of donor oocytes available is severely limited. Taken together, and in light of the trend in Israel as elsewhere of women delaying childbirth for non-medical reasons, there are a very large number of older women undergoing IVF. Indeed, 31% of patients undergoing oocyte retrieval in the authors unit in 2004 were older than 40 years of age. The purpose of this study is to summarize the experience of treating infertile women between 40 and 46 years of age, with a year-by-year analysis of outcomes in order to provide specific information for counselling. Materials and methods All patient data from women who were 40 years of age at the time of IVF treatment during the years 1995 to 2004 were retrospectively analysed. All initiated cycles during this period were evaluated; frozen thawed cycles and egg donation treatments were not included. The same clinical and embryology team was involved in all treatments. All patients had undergone diagnostic hysteroscopy or hysterosalpingography prior to treatment initiation to document a normal uterine cavity. Serum FSH was analysed once before commencement of IVF treatment. Patients who had repeated FSH > 20 IU/ml were not treated. Ovarian stimulation was carried out by one of the following protocols depending on previous or estimated ovarian response: (i) the long desensitizing protocol using the gonadotrophin-releasing hormone agonist (GnRHa) D-Trp-6-LHRH (Decapeptyl; Ferring, Kiel, Germany) 0.1 mg/day given subcutaneously from the mid-luteal phase of the preceding cycle (days 21 23); (ii) the short protocol in which the same dose of GnRHa is administered from day 1 of the cycle; (iii) the ultra-short protocol, in which premature ovulation was avoided by the administration of decapeptyl 0.05 mg/day for the first 3 days of the cycle only; (iv) GnRH antagonist protocol using gonadotrophin stimulation starting from day 2 with addition of a GnRH antagonist (Cetrotide; Serono International, Switzerland) 0.25 mg/day when the leading follicle achieved a diameter of 14 mm; (v) unprotected treatment cycles, in which no pituitary desensitization was attempted; and (vi) natural IVF cycles, in which no ovarian stimulation was used (Fasouliotis et al., 2000). Ovulation induction protocols involved human menopausal gonadotrophin (HMG, Pergonal; Teva, Petah Tiqua, Israel), or Menogon (Ferring Pharmaceuticals, Malmo, Sweden), urinary FSH (Metrodin; Serono), recombinant FSH (Gonal- F; Serono), or a combination of both. Ovarian response was monitored at 2- to 3-day intervals by vaginal sonography and serum oestradiol concentration measurements. Oestradiol was measured by a solid-phase ligand-labelled competitive chemiluminescence immunoassay (Immulite; DPC, Los Angeles, CA, USA). Retrieved oocytes were, according to sperm quality, either inseminated by conventional IVF or by intracytoplasmic sperm injection (ICSI) as previously described (Simon et al. 1998). Fertilized oocytes were cultured in either human tubal fluid or P1 medium (Irvine Scientific, Santa Ana, CA, USA) each enriched with 10% synthetic serum substitute (SSS, Irvine Scientific) until day 3 of fertilization when embryo transfer took place. The luteal phase was supported by intravaginal micronized progesterone (Uterogestan, Besins-Iscovesco, Paris, France) in three divided doses up to a total amount of 900 mg/day, or by progesterone in oil (Gestone; Paines and Byrne Limited, West Byfleet, Surrey, UK) starting 1 day after oocyte retrieval. Women were tested for serum β-human chorionic gonadotrophin (β-hcg) concentrations 14 days after embryo transfer. If the pregnancy test was positive, the pregnancy was monitored by serial ultrasounds to determine fetal viability. Clinical pregnancy was defined as the presence of an intrauterine gestational sac using transvaginal ultrasound. When pregnancy occurred, luteal support was continued until 10 weeks of gestation. Statistical analysis Pregnancy rates were analysed with the two-tailed Fisher s Exact test. For larger contingency tables, the chi-squared test was used, including the test for linearity. Quantitative variables were compared between groups by a two-sample t-test. A logistic regression model was applied to outcome (pregnancy in a treatment cycle) in order to assess the simultaneous effect of variables which were significant in the univariate comparison of cycles ending with and without pregnancy. The adjusted odds ratio was calculated for each of the independent variables in the model. A P-value of <0.05 was considered statistically significant. Results Demographic data During the study period, 1217 treatment cycles were initiated in 381 women in this age group. As shown in Table 1, the majority of women had unexplained, male factor, or mechanical infertility. About 15% of women had combined diagnoses, mostly including a mechanical factor. Mean age at treatment was 41.9 ± 1.8 (range 40 46) years. Mean FSH concentration at the beginning of IVF was 8.6 ± 6.6 IU/ml. Mean number of treatment cycles was 3.3 ± 2.8 (range 1 15). Only 32% of these women had delivered previously. IVF treatments The long protocol was used in 189 (15.5%) cycles; the short protocol was used in 683 cycles (56.1%); and in 183 cycles (15.0%), GnRH antagonist was given. The mean number of ampoules (75 IU each) of various gonadotrophins/cycle was 51 ± 25 (range: 4 174) ampoules/cycle. Additional details regarding ovarian and endometrial response are summarized in Table

3 Table 1. Cause of infertility, reproductive history and FSH concentrations of 381 IVF patients aged 40 years and above. Parameter Per cent of all patients Cause of infertility Unexplained 31 Male factor 29 Mechanical factor 19 Anovulation 1.8 Endometriosis 2.7 Combined factors 15.3 IVF treatment before age 40 None 53.5 Successful 16.5 Unsuccessful 30 Number of previous pregnancies Number of previous deliveries >2 2.9 Table 2. Treatment details of 1217 IVF cycles in 381 women aged 40 and above. GnRH = gonadotrophin-releasing hormone; HCG = human chorionic gonadotrophin; ICSI = intracytoplasmic sperm injection. Treatment details Per cent of Mean ± SD all cycles (range) 350 Type of gonadotrophin Urinary menotropin 77.0 Recombinant FSH 9.5 Combined urinary and recombinant 8.5 None (spontaneous cycle) 5.0 No. of 75 IU gonadotrophin ampoules per cycle All cycles 51 ± 25 Long protocol (n = 189) 43 ± 21 Short protocol (n = 683) 50 ± 24 Ultrashort protocol (n = 12) 55 ± 21 GnRH antagonist protocol (n = 183) 55 ± 25 Gonadotrophins only (n = 81) 61 ± 32 No. of follicles 18 mm on HCG day 1.9 ± 2.4 Serum oestradiol on HCG day (pmol/l) 3670 ± 4240 Endometrium thickness on HCG day (mm) 9.0 ± 2.4 Method of fertilization IVF 29.5 ICSI 67 Both 3.5 No. of oocytes retrieved 4.3 ± 4.7 (0 35) Embryos transferred per cycle

4 Cancellation, oocyte retrieval, and embryo transfer rates Of 1217 initiated cycles, 202 (16.6%) did not reach oocyte retrieval. The main reason for cancellation was low response to ovarian stimulation. Other reasons for cancellation included premature luteinization, ovarian cysts, and unfavourable or inadequate endometrium for embryo transfer. Additionally, in 52 treatment cycles (4.3%) in which oocyte retrieval was performed, no oocytes were retrieved. The mean number of oocytes/cycle when retrieval was performed was 5.1 ± 4.5. Embryos were transferred in only 762 treatment cycles (62.6%), but this rate rose to 79% in cycles in which oocyte retrieval was performed. The mean number of embryos transferred was 2.7 ± 1.4 (range 1 6). Notably, in 20% of cycles more than three embryos were transferred (Table 2). Additional details are summarized in Table 3. Outcome There were 88 pregnancies. Overall pregnancy rates (PR) and delivery rates (DR) per initiated cycle were 7.3 and 4.7% respectively. No woman had more than one delivery. Treatment outcome, stratified according to age at treatment, is presented in Table 3. There was one additional extrauterine pregnancy not included in the summary. Pregnancy loss rate was 33%, i.e. 57 women delivered successfully (15% of all patients). There were a total of 62 babies. A statistically significant decline in PR and DR was noted with age (Figure 1), starting at 13.9 and 9.1% respectively for age 40 years and declining to 2.8 and 0.7% respectively at age 45 years (P < 0.001). There were 52 singleton deliveries, 50 of which were delivered after 37 weeks of gestation. The rate of Caesarean sections was 50%. The mean birth weight was 2890 g, but five babies weighed <2500 g. All the babies had Apgar scores at 1 and 5 min of >7; no major complications were recorded during pregnancy or at birth. Two singleton pregnancies ended with a preterm delivery before 37 weeks. One patient had placental abruption requiring emergency delivery by Caesarean section at 25 weeks; the baby weighed 890 g and died of complications of prematurity at 3 weeks. The second patient had a spontaneous preterm delivery at 26 weeks; the baby weighed 715 g and was discharged from the neonatal unit after several weeks. Five of the 88 pregnancies were twins: all five delivered after 35 weeks of gestation, with the mean birth weight 2400 g (range: ). No neonatal complications were recorded at birth. Stratified by age, the rate of successful pregnancy outcome declined from 16.7% at 40 years to 3.3% at 45 years (Table 3). None of 10 patients treated after age 45 years delivered a baby. Cumulative pregnancy rates Calculated pregnancy rates per treatment cycle (for all women) were 3.2, 5.4 and 5.7% in the first, second, and third treatment cycle respectively (Figure 2). Thus, 75% of all pregnancies were achieved in the first two treatment cycles; only three of 88 (3.4%) pregnancies occurred after the sixth cycle of treatment. Factors influencing outcome In order to identify possible modifiers, women who became pregnant, and treatment cycles in which pregnancy was achieved, were compared with women and treatment cycles that were not successful. Women who became pregnant were younger, and had a smaller number of treatment cycles prior to conception. Treatment cycles resulting in pregnancy were characterized by the following: smaller dose of gonadotrophins, endometrial thickness > 8.5 mm, and a greater number of follicles, oocytes, and embryos transferred. Ovarian stimulation protocol, type of gonadotrophins, and fertilization technique (conventional IVF or ICSI) were not significantly different between successful pregnancy cycles and failed ones. Other clinical variables including IVF treatment before age 40 years, pregnancies before age 40 years, and cause of infertility, were also not significantly different between women who became pregnant and those who did not. In analysis of FSH assays, no correlation between elevated FSH and pregnancy or delivery rates was observed, whether a cut-off of either 10 or 15 IU/ml was employed or not. In multivariate logistic regression analysis of patient and treatment variables, the following factors were independently and significantly related to pregnancy: age at treatment (adjusted OR for clinical pregnancy 0.76, 95% CI ), mean number of gonadotrophin ampoules (OR 0.98, 95% CI ), number of follicles 18 mm (OR 1.11, 95% CI ), endometrial thickness > 8.5 mm (OR 1.9, 95% CI ), and number of embryos transferred (OR 1.32, 95% CI ). The number of collected oocytes (as a reflection of ovarian response) was positively related to treatment success. When a cut-off limit of four oocytes was chosen as an indicator of a good ovarian response, it was found that while a significantly higher pregnancy rate was achieved by the younger women (ages years, P > ) who attained this criterion, the effect was blunted in older patients (Table 4). Similarly, for all the women, both pregnancy and delivery rates increased when more embryos were transferred. The mean number of embryos transferred was 2.7, but in 32% of cycles 3 embryos were replaced. Transfer of 3 embryos correlated with a higher pregnancy rate in younger women (ages years, P < ), but did not reach statistic significance in older women (Table 5). 351

5 Table 3. Outcome of 1217 IVF cycles in 381 women aged 40 years and older, stratified according to age. Parameter Patient age during IVF cycle All ages No. of patients (%) 114 (30) 69 (18) 71 (19) 44 (12) 43 (11) 30 (8) 10 (3) 381 No. of treatment cycles (%) 209 (17) 230 (19) 237 (19) 199 (16) 150 (12) 143 (12) 49 (4) 1217 Cancellation prior to oocyte retrieval (%) Mean no. of oocytes retrieved Mean no. of embryos transferred No. of clinical pregnancies No. of live births Pregnancy rate per initiated cycle (%) a Miscarriage rate (%) Delivery rate per initiated cycle (%) a Patients having a live birth (%) a Significant association between age and outcome (P < 0.01), with a significant linear trend (P < 0.001) Pregnancy rate Delivery rate % Pregnancy rate (% of initiated cycles) Age (years) No. of IVF cycles Figure 1. Pregnancy and delivery rates per initiated cycle according to age. Figure 2. Cumulative pregnancy rates in 1217 IVF treatment cycles in 318 women aged 40 years and above. 352

6 Table 4. Effect of number of oocytes retrieved on pregnancy rates at different age subgroups. Age (years) Cycles with 1 4 oocytes Cycles with 5 oocytes P-value Total no. No. of Total no. No. of of cycles pregnancies of cycles pregnancies (%) (%) (4.6) (18.5) < (8.0) (15.0) (1.6) (8.0) Table 5. The effect of the number of embryos transferred at different age subgroups on pregnancy rate. NS = not statistically significant. Age (years) 1 2 embryos transferred 3 embryos transferred P-value Total no. No. of Total no. No. of of cycles pregnancies of cycles pregnancies (%) (%) (0.7) (21.0) < (11.0) (15.0) NS (2.3) 94 8 (8.5) NS Discussion Most data on IVF outcome in older patients derive from multicentre experience and national registries, which, by their nature, include disparate data as a single cohort (American Society for Reproductive Medicine, 2004; Andersen et al., 2005). In addition, there is rarely a breakdown of rates of pregnancy and delivery by year from 40 to 46 years of age. The results reported herein comprise a single centre experience in older women, reported according to age at treatment. So far as is known, this is the largest report on IVF in women aged 40 years and older. In a broad sense, the present experience underscores that of Klipstein et al. from a very large infertility centre with 1263 women undergoing 2705 cycles: there was a gradual decrease in both pregnancy and delivery rates with each year over 40 years and there were no successful pregnancies when IVF treatment was begun after the age of 44 years (Klipstein et al., 2005). Klipstein reported a pregnancy rate of 28% if IVF was started after age 40 years, but 53% of cycles in that cohort were performed in the younger women (40 41 years) relative to only 36% of cycles in the present group. In an earlier report (Lass et al., 1998) in a total of 1087 cycles in 471 women between the ages of years, the pregnancy rate was 11.3%, with a sharp decline in success after the age of 42 years. The present experience also implies that the age of the woman at advent of treatment is a critical variable, but in this series the majority of women (64%) were aged >42 years, relative to earlier reports. A review of the literature confirms that the international experience is better in women years of age: the results in women years are different from those in women years of age, which in turn, are different from those above the age of 45 at the start of treatments. In a series of 163 women 40 years who had undergone 713 IVF cycles, the pregnancy and delivery rates were 16.6 and 10% respectively; of these, 60% were in women aged years of age (Widra et al., 1996). Similar results were seen in 431 IVF cycles in women aged 41 years and older (Ron-El et al., 2000), and in 736 ICSI cycles in women aged 40 years and older (Grimbizis et al., 1998). In the latter study, for example, 53% of women were aged years: embryos were transferred in 78% of initiated cycles, with clinical pregnancy and viable pregnancy rates per started cycle 11 and 7% respectively; a significant trend for fewer pregnancies and deliveries with each year of age was noted. Thus, in a report of oldest women, 708 cycles initiated in women aged years of age, pregnancy rate per initiated cycles was only 6.6% (Orvieto et al., 2004). Women who conceived had a better ovarian response, expressed by higher serum oestradiol concentrations on HCG day, number of oocytes and embryos and lower doses of gonadotrophins used. This observation corroborates similar previous reports demonstrating the importance of a good ovarian response (Lass et al., 1998; Çiray et al., 2006). The ovarian response was invariably better in women aged years relative to the older women. 353

7 354 As in reports by others, IVF treatment before age 40 years, pregnancies before age 40 years, basal FSH concentrations at advent of IVF, and cause of infertility did not significantly differ between women who became pregnant relative to those who did not. The fact that previous pregnancies did not improve pregnancy and delivery rates in older women undergoing assisted technology is unexpected and is in contradiction to the authors own experience (Laufer et al., 2004) in spontaneous pregnancies above age 45 years in grandmultiparous women. In the authors experience, basal FSH was not predictive of pregnancy and delivery rates. These observations should be interpreted with caution since FSH was measured prior to commencing IVF, and women who had repeated FSH over 20 IU/ml were not treated. As reported by others, the number of embryos transferred significantly influenced pregnancy and delivery rates (Widra et al., 1996; Ron-El et al., 2000; Opsahl et al., 2001; Klipstein et al., 2005); however, multi-fetal pregnancies are not common, and in this study as in others, twins were the only non-singleton births regardless of the number of embryos transferred. All twin pregnancies in this series went to term, highlighting the experience of others that multiple transfers may achieve acceptable pregnancy and delivery rates in older women without a concomitant increase in multi-fetal pregnancies and their complications. Recently, Heijnen have shown that in a slightly younger group of IVF patients, transfer of two embryos achieved similar pregnancy rates to transfer of three embryos with a significant reduction in multi-fetal pregnancies, although more treatment cycles will be needed (Heijnen et al., 2006). Another important difference between the present series and that of Klipstein et al. (2005) was that women who requested to continue beyond two cycles were allowed to carry on. The mean number of treatment cycles per patient in the present group was 3.3 versus 2.3 in the Klipstein study. Unlike most reports in the literature, Israeli women enjoy the availability of health care coverage for several cycles of IVF, even as the success rate declines. Since health policy in Israel does not strictly limit the number of treatment cycles per patient, it was possible to assess the biological potential for IVF success in older women. In conclusion, the present study suggests the following: (i) unnecessary delays in advent of treatment should be avoided; (ii) the effect of each year of age is very important in predicting rates of pregnancy and delivery; (iii) the woman s previous history, including cause of infertility and/or previous pregnancies and deliveries, does not affect the chances for conception with IVF at an older age; (iv) transfer of multiple embryos increases the chances of success without concomitant increased risk for multi-fetal pregnancies, although experience with twin pregnancies was good; (v) importantly, virtually all of the pregnancies that resulted in deliveries were uneventful and the majority of the babies born were healthy; and finally (vi) it is recommended that women should not consider starting IVF after the age of 44 years. With respect to the latter point, it may be illustrative to note that with regard to number of cycles, 75% of pregnancies in the present study occurred in the first two cycles, and 97% in the first six cycles. Among women aged years, one in five to one in seven women had a baby, but fewer than one in 10 at age 44 years. With respect to the number of pregnancies achieved in the very oldest women, only one in 30 women undergoing a total of 143 IVF cycles at age 45 years had a baby, a rate very similar to those reported by others. No woman treated at an older age had a delivery. Thus, it is instructive to note that these results underscore the caveat that IVF in older women should be limited to a handful of cycles at most, and that IVF in women aged older than 45 years using their own oocytes is unjustified. These caveats should be taken into consideration when assessing IVF treatment in older women, in order to avoid unrealistic expectations. References American Society for Reproductive Medicine 2004 Assisted reproductive technology in the United States 2004; 2000 results generated from the American Society for Reproductive Medicine/ Society for Assisted Reproductive Technology Registry. Fertility and Sterility 81, Andersen AN, Gianaroli L, Felberbaum R et al Assisted reproductive technology in Europe, Results generated from European registers by ESHRE. Human Reproductionu 20, Antinori S, Gholami GH, Versaci C et al Obstetric and prenatal outcome in menopausal women: a 12-year clinical study. Reproductive BioMedicine Online 6, Armstrong DT 2001 Effects of maternal age on oocyte developmental competence. Theriogenology 55, Baird DT, Collins J, Egozcue J et al Fertility and ageing. Human Reproduction Update 11, Chambers GM, Ho MT, Sullivan EA 2006 Assisted reproductive technology treatment costs of a live birth: an age-stratified costoutcome study of treatment in Australia. Medical Journal of Australia 184, Check JH, Lurie D, Callan C et al Comparison of the cumulative probability of pregnancy after in vitro fertilizationembryo transfer by infertility factor and age. Fertility and Sterility 61, Çiray HN, Ulug U, Tosun S et al Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of age and over. Reproductive BioMedicine Online 13, Fasouliotis SJ, Simon A, Laufer N 2000 Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. Journal of Assisted Reproduction and Genetics 17, Grimbizis G, Vandervorst M, Camus M et al Intracytoplasmic sperm injection, results in women older than 39, according to age and the number of embryos replaced in selective or non-selective transfers. Human Reproduction 13, Heijnen EM, Klinkert ER, Schmoutziguer AP et al Prevention of multiple pregnancies after IVF in women 38 and older: a randomized study. Reproductive BioMedicine Online 13, Klipstein S, Regan M, Ryley DA et al One last chance for pregnancy: a review of 2,705 in vitro fertilization cycles initiated in women age 40 years and above. Fertility and Sterility 84, Lass A, Croucher C, Duffy S et al One thousand initiated cycles of in vitro fertilization in women 40 years of age. Fertility and Sterility 70, Laufer N, Simon A, Samueloff A et al Successful spontaneous pregnancies in women older than 45 years. Fertility and Sterility 81, Legro RS, Shackleford DP, Moessner JM et al ART in women 40 and over. Is the cost worth it? Journal of Reproductive Medicine 42, Opsahl MS, Blauer KL, Black SH et al The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing. Journal of Assisted Reproduction and Genetics 18, Orvieto R, Bar-Hava I, Yoeli R et al Results of in vitro fertilization cycles in women aged years. Gynecologic Endocrinology 18,

8 Ron-El R, Raziel A, Strassburger D et al Outcome of assisted reproductive technology in women over the age of 41. Fertility and Sterility 74, Simon A, Holzer H, Hurwitz A et al Comparison of cryopreservation outcome following intracytoplasmic sperm injection and conventional in vitro fertilization. Journal of Assisted Reproduction and Genetics 15, te Velde ER, Pearson PL 2002 The variability of female reproductive ageing. Human Reproduction Update 8, Widra EA, Gindoff PR, Smotrich DB et al Achieving multipleorder embryo transfer identifies women over 40 years of age with improved in vitro fertilization outcome. Fertility and Sterility 65, Ziebe S, Loft A, Petersen JH et al Embryo quality and developmental potential is compromised by age. Acta Obstetricia et Gynecologica Scandinavica 80, Received 16 October 2006; refereed 22 November 2006; accepted 12 January

Abstract. Introduction. RBMOnline - Vol 19. No Reproductive BioMedicine Online; on web 24 August 2009

Abstract. Introduction. RBMOnline - Vol 19. No Reproductive BioMedicine Online;  on web 24 August 2009 RBMOnline - Vol 19. No 4. 2009 599 603 Reproductive BioMedicine Online; www.rbmonline.com/article/3872 on web 24 August 2009 Article Assisted reproduction in women over 40 years of age: how old is too

More information

Abstract. Introduction. Materials and methods. Patients and methods

Abstract. Introduction. Materials and methods. Patients and methods RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos

More information

Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older

Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa

More information

Article Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of age and over

Article Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of age and over RBMOnline - Vol 13. No 4. 2006 516-522 Reproductive BioMedicine Online; www.rbmonline.com/article/2391 on web 15 August 2006 Article Outcome of 1114 ICSI and embryo transfer cycles of women 40 years of

More information

Abstract. Introduction. Materials and methods

Abstract. Introduction. Materials and methods RBMOnline - Vol 10. No 5. 2005 645 649 Reproductive BioMedicine Online; www.rbmonline.com/article/1518 on web 18 March 2005 Article Factors predicting IVF treatment outcome: a multivariate analysis of

More information

A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort

A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,

More information

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi

More information

Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment

Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,

More information

Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles

Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park

More information

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic

More information

Embryo Selection after IVF

Embryo Selection after IVF Embryo Selection after IVF Embryo Selection after IVF Many of human embryos produced after in vitro fertilization carry abnormal chromosomes. Placing a chromosomally normal embryo (s) into a normal uterus

More information

Infertility treatment

Infertility treatment In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation

More information

Article Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial

Article Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial RBMOnline - Vol 16. No 3. 2008 361-367 Reproductive BioMedicine Online; www.rbmonline.com/article/3193 on web 21 January 2008 Article Vaginal gel versus intramuscular progesterone for luteal phase supplementation:

More information

NICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic

NICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic NICE fertility guidelines Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic About the LWC 4 centres around the UK London Cardiff Swansea Darlington The largest sperm bank in

More information

Ovarian response in three consecutive in vitro fertilization cycles

Ovarian response in three consecutive in vitro fertilization cycles FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in

More information

I. ART PROCEDURES. A. In Vitro Fertilization (IVF)

I. ART PROCEDURES. A. In Vitro Fertilization (IVF) DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment

More information

Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination

Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination RBMOnline - Vol 13. No 2. 2006 208-212 Reproductive BioMedicine Online; www.rbmonline.com/article/2334 on web 30 May 2006 Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine

More information

Analysis of factors affecting embryo implantation

Analysis of factors affecting embryo implantation Analysis of factors affecting embryo implantation Andrew L.Speirst, H.W.G.Baker and Nusratudin Abdullah The Royal Women's Hospital, Melbourne, Australia ITo whom correspondence should be addressed Introduction

More information

Modified natural cycle IVF and mild IVF: a 10 year Swedish experience

Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Reproductive BioMedicine Online (2010) 20, 156 162 www.sciencedirect.com www.rbmonline.com ARTICLE Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Arthur Aanesen *, Karl-Gösta Nygren,

More information

Assisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi

Assisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various

More information

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles? J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation

More information

Blastocyst-stage embryo transfer in patients who failed to conceive in three or more day 2 3 embryo transfer cycles: a prospective, randomized study

Blastocyst-stage embryo transfer in patients who failed to conceive in three or more day 2 3 embryo transfer cycles: a prospective, randomized study FERTILITY AND STERILITY VOL. 81, NO. 3, MARCH 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Blastocyst-stage embryo transfer

More information

IVF treatment should not be postponed for patients with high basal FSH concentrations

IVF treatment should not be postponed for patients with high basal FSH concentrations Reproductive BioMedicine Online (2010) 21, 631 635 www.sciencedirect.com www.rbmonline.com SHORT COMMUNICATION IVF treatment should not be postponed for patients with high basal FSH concentrations Ettie

More information

Neil Goodman, MD, FACE

Neil Goodman, MD, FACE Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects

More information

LOW RESPONDERS. Poor Ovarian Response, Por

LOW RESPONDERS. Poor Ovarian Response, Por LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients

More information

Understanding Infertility, Evaluations, and Treatment Options

Understanding Infertility, Evaluations, and Treatment Options Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly

More information

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr. Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art

More information

A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of

A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group

More information

Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation

Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation

More information

Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles

Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra

More information

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin

More information

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve

More information

Hana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang

Hana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang Original Article Obstet Gynecol Sci 2015;58(6):481-486 http://dx.doi.org/10.5468/ogs.2015.58.6.481 pissn 2287-8572 eissn 2287-8580 Effect of second-line surgery on in vitro fertilization outcome in infertile

More information

Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE

Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE Human Reproduction, Vol.1, No.1 pp. 1 21, 2009 doi:10.1093/humrep/dep035 Hum. Reprod. Advance Access published February 18, 2009 ORIGINAL ARTICLE ESHRE Assisted reproductive technology and intrauterine

More information

in vitro fertilization

in vitro fertilization FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal

More information

Universal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D.

Universal Embryo Cryopreservation: Frozen versus Fresh Transfer. Zaher Merhi, M.D. Universal Embryo Cryopreservation: Frozen versus Fresh Transfer Zaher Merhi, M.D. Disclosure: None Fewer complications with IVF 1.5% children in US are born through ART 1.1 million children since 2006

More information

How to make the best use of the natural cycle for frozen-thawed embryo transfer?

How to make the best use of the natural cycle for frozen-thawed embryo transfer? How to make the best use of the natural cycle for frozen-thawed embryo transfer? Ariel Weissman, MD IVF Unit, Dep. Ob/Gyn Wolfson Medical Center, Holon Sackler Faculty of Medicine, Tel Aviv University

More information

Study on Several Factors Involved in IVF-ET of Human Beings

Study on Several Factors Involved in IVF-ET of Human Beings Study on Several Factors Involved in IVF-ET of Human Beings Lei X 1, Zhuoran W 1, Bin L 1, Huiming L 1, Hongxiu Z 1, Yajuan Z 1, Yingbo Q 1, Guixue Z 2 1 The First Clinical College of Harbin Medical University,

More information

IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW

IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150

More information

Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.

Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health. Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive

More information

Article Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles

Article Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles RBMOnline - Vol 17. No 2. 2008 190-198 Reproductive BioMedicine Online; www.rbmonline.com/article/3332 on web 19 June 2008 Article Highly purified HMG versus recombinant FSH for ovarian stimulation in

More information

Follicular diameters in conception cycles with and without multiple pregnancy after stimulated ovulation induction

Follicular diameters in conception cycles with and without multiple pregnancy after stimulated ovulation induction Human Reproduction Page 1 of 5 Hum. Reprod. Advance Access published December 17, 2004 doi:10.1093/humrep/deh677 Follicular diameters in conception cycles with and without multiple pregnancy after stimulated

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,

More information

Fertility assessment and assisted conception

Fertility assessment and assisted conception Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.

More information

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,

More information

The old IVF patient: An evidence based approach. Stratis Kolibianakis MD MSc PhD

The old IVF patient: An evidence based approach. Stratis Kolibianakis MD MSc PhD The old IVF patient: An evidence based approach Stratis Kolibianakis MD MSc PhD Unit for Human Reproduction 1 st Dept Ob/Gyn Aristotle University of Thessaloniki No conflict of interest How old is old?

More information

Infertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF

Infertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility

More information

Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used

Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara

More information

Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration

Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration Wu et al. Reproductive Biology and Endocrinology 2014, 12:96 RESEARCH Open Access Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH

More information

Article Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles

Article Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles RBMOnline - Vol 6. No 4. 439 443 Reproductive BioMedicine Online; www.rbmonline.com/article/872 on web 7 April 2003 Article Conception rates following assisted reproduction in poor responder patients:

More information

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER *40639* 40639 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IVF WITH EMBRYO TRANSFER I have requested treatment by the physicians and (Print Patient s name) staff of the Women & Infants Fertility

More information

Dr Manuela Toledo - Procedures in ART -

Dr Manuela Toledo - Procedures in ART - Dr Manuela Toledo - Procedures in ART - Fertility Specialist MBBS FRANZCOG MMed CREI Specialities: IVF & infertility Fertility preservation Consulting Locations East Melbourne Planning a pregnancy - Folic

More information

Fertility Policy. December Introduction

Fertility Policy. December Introduction Fertility Policy December 2015 Introduction Camden Clinical Commissioning Group (CCG) is responsible for commissioning a range of health services including hospital, mental health and community services

More information

2017 United HealthCare Services, Inc.

2017 United HealthCare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017

More information

Article Prediction of pituitary down-regulation by evaluation of endometrial thickness in an IVF programme

Article Prediction of pituitary down-regulation by evaluation of endometrial thickness in an IVF programme RBMOnline - Vol 8. No 5. 2004 595-599 Reproductive BioMedicine Online; www.rbmonline.com/article/1065 on web 17 March 2004 Article Prediction of pituitary down-regulation by evaluation of endometrial thickness

More information

Patient Overview: Invitro Fertilisation

Patient Overview: Invitro Fertilisation Patient Overview: Overview IVF stands for in-vitro fertilisation i.e. literally fertilisation in a glass dish. You may also hear the term ART used which stands for Assisted Reproductive Technologies. IVF

More information

Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome

Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome British Journal of Obstetrics and Gynaecology January 1998, Vol. 105, pp. 107-1 12 Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome Khaldoun Sharif Lecturer, Manal

More information

Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over

Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 217;44(2):111-117 Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 4 and over Hye

More information

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. *40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print

More information

Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial

Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial Christine S. Goudge, M.D., Theodore C. Nagel, M.D., and Mark A. Damario, M.D. Division

More information

Adoption and Foster Care

Adoption and Foster Care GLOSSARY Family building via Adoption and Foster Care October 2018 www.familyequality.org/resources A Anonymous Donor: A person who donated sperm or eggs with the intention of never meeting resulting children.

More information

COMMISSIONING POLICY. Tertiary treatment for assisted conception services

COMMISSIONING POLICY. Tertiary treatment for assisted conception services Final Version COMMISSIONING POLICY Tertiary treatment for assisted conception services Designated providers for patients registered with a Worcestershire GP BMI The Priory Hospital, Birmingham - 1 - Commissioning

More information

NHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs

NHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO

More information

Minimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology

Minimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication

More information

Principles of Ovarian Stimulation

Principles of Ovarian Stimulation Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle

More information

Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study

Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a

More information

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn) 34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh

More information

Puerto Rico Fertility Center

Puerto Rico Fertility Center Puerto Rico Fertility Center General Information of the In-Vitro Fertilization Program Dr. Pedro J. Beauchamp First test-tube baby IN PUERTO RICO Dr. Pedro Beauchamp with Adlin Román in his arms. Paseo

More information

A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist

A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist 1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang

More information

Ivf day 6 estradiol level

Ivf day 6 estradiol level Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3

More information

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...

More information

% Oocyte Donation Pregnancyes (days 3)

% Oocyte Donation Pregnancyes (days 3) Ovulation induction in oocyte donors Roma- September 2007 Dr. José Remohí Dr. Carmen Rubio Dr. Amparo Mercader Dr. Pilar Alama Dr. Marco Melo Evolution of oocyte donation cycles 1500 1500 1000 58% 661

More information

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations

Infertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should

More information

Managing infertility when adenomyosis and endometriosis co-exist

Managing infertility when adenomyosis and endometriosis co-exist Managing infertility when adenomyosis and endometriosis co-exist Jinhua Leng Beijing,China Endometriosis Endometriosis (EM) is a common, benign, ovary hormone-dependent gynecologic disorder which affects

More information

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.018.MH Last Review Date: 08/04/2016 Effective Date: 01/01/2017

MedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: PA.018.MH Last Review Date: 08/04/2016 Effective Date: 01/01/2017 MedStar Health, Inc. POLICY AND PROCEDURE MANUAL PA.018.MH Infertility- Treatment This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP (Not Covered) MedStar

More information

Optimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE

Optimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers

More information

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist

More information

Article Evaluation of functional ovarian reserve in 60 patients

Article Evaluation of functional ovarian reserve in 60 patients RBMOnline - Vol 7. No 2. 200 204 Reproductive BioMedicine Online; www.rbmonline.com/article/846 on web 12 June 2003 Article Evaluation of functional ovarian reserve in 60 patients Dr Giuseppe Loverro Giuseppe

More information

Infertility. Thomas Lloyd and Samera Dean

Infertility. Thomas Lloyd and Samera Dean Infertility Thomas Lloyd and Samera Dean Infertility Definition Causes Referral criteria Assisted reproductive techniques Complications Ethics What is infertility? Woman Reproductive age Has not conceived

More information

Pediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain

Pediatrics, Obstetrics and Gynecology, University School of Medicine, Valencia University, Valencia, Spain Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study María-José Escribá, Ph.D.,

More information

Recent Developments in Infertility Treatment

Recent Developments in Infertility Treatment Recent Developments in Infertility Treatment John T. Queenan Jr., MD Professor, Dept. Of Ob/Gyn University of Rochester Medical Center Rochester, NY Disclosures I don t have financial interest or other

More information

Sample size a Main finding b Main limitations

Sample size a Main finding b Main limitations 1 Table 1. Available studies on the relation between endometriosis and miscarriage (1995-2015). Study (citation) Country Study period Study design Sample size a Main finding b Main limitations Matoras

More information

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,

More information

WHAT IS A PATIENT CARE ADVOCATE?

WHAT IS A PATIENT CARE ADVOCATE? WHAT IS A PATIENT CARE ADVOCATE? Fertility treatments can be overwhelming. As a member, you have unlimited access to a dedicated Patient Care Advocate (PCA), who acts as your expert resource for discussing

More information

The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age

The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G

More information

Article Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study

Article Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study RBMOnline - Vol 15. No 2. 2007 134-148 Reproductive BioMedicine Online; www.rbmonline.com/article/2711 on web 13 June 2007 Article Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective

More information

CLINICAL ASSISTED REPRODUCTION

CLINICAL ASSISTED REPRODUCTION Journal of Assisted Reproduction and Genetics, Vol. 17, No. 4. 2000 CLINICAL ASSISTED REPRODUCTION CLINICAL ASSISTED REPRODUCTION Effect of Clinical and Semen Characteristics on Efficacy of Ovulatory Stimulation

More information

ORIGINAL ARTICLE ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES

ORIGINAL ARTICLE ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES Asha Verma 1, Rekha Mulchandani 2, Nupur Lauria 3, Kusum Verma 4, Sunita Himani 5 HOW TO CITE THIS ARTICLE: Asha Verma, Rekha Mulchandani, Nupur

More information

Fertility treatment and referral criteria for tertiary level assisted conception

Fertility treatment and referral criteria for tertiary level assisted conception Fertility treatment and referral criteria for tertiary level assisted conception Version Number 2.0 Ratified by HVCCG Exec Team Date Ratified 9 th November 2017 Name of Originator/Author Dr Raj Nagaraj

More information

Infertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem?

Infertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem? Infertility (female factors). In another one third of cases, infertility is due to the man (male factors). The remaining cases are caused by a mixture of male and female factors or by unknown factors.

More information

Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer

Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer FERTILITY AND STERILITY Copyright tl 1989 The American Fertility Society Printed on acid-free paper in U. S.A. Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization

More information

Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018)

Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Islington CCG Fertility Policy First approved: 29 January 2015 Policy updated: November 2018 (approved by Haringey and Islington s Executive Management Team on 5 December 2018) Introduction Islington CCG

More information

Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium

Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium FERTILITY AND STERILITY VOL. 79, NO. 6, JUNE 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Hyaluronic acid can successfully

More information

Realizing dreams booklet.indd 1 5/20/ :26:52 AM

Realizing dreams booklet.indd 1 5/20/ :26:52 AM Realizing dreams. 18891booklet.indd 1 5/20/2010 11:26:52 AM The Journey To Parenthood The first Gator Baby was born in 1988 through the in vitro fertilization program at the University of Florida. Since

More information

INDICATIONS OF IVF/ICSI

INDICATIONS OF IVF/ICSI PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian

More information